Improved DFS in most of the trials with adjuvant EGFR-TKIs in EGFR mutant patients in stage IB-IIIA adenocarcinoma (for example ADAURA trial) promises the change of current practice in these patients [12,33,34,35,36]. The gene discussed is EGFR; the disease is adenocarcinoma.